Skip to main content

Specialty Pharmacy

  • FDA approves Humira biosimilar Amjevita from Amgen

    SILVER SPRING, Md. — The Food and Drug Administration has approved Amgen’s Amjevita (adalimumab-atto), a biosimilar of AbbVie’s Amgen (adalimumab) and the fourth U.S. biosimilar, the company announced Friday. The drug — Amgen’s first biosimilar — is indicated to treat seven inflammatory conditions, among them moderate to severe rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis and moderate to severe chronic plaque psoriasis. 
     

  • Pfizer decides against splitting Essential Health, Innovative Health divisions

    NEW YORK — After a period of evaluation, Pfizer announced Monday that its board of directors and executive leadership team had decided not to split the company into two separate companies, Pfizer Innovative Health and Pfizer Essential Health. The two will remain separately managed units within Pfizer. 
     

  • Allergan acquires Akarna Therapeutics

    DUBLIN — On the same day that it announced the acquisition of Tobira Therapeutics, Allergan acquired Akarna Therapeutics, a biotech company that, like Tobira, focuses on developing treatments for nonalcoholic steatohepatitis (NASH), a severe type of fatty liver disease.
     

  • PhRMA brings scientists to Capitol Hill

    WASHINGTON — The Pharmaceutical Research and Manufacturers of America (PhRMA) on Wednesday brought 60 of its member companies’ researchers to Capitol Hill for meetings with members of Congress. The researchers will discuss with lawmakers how they can support developing new, innovative medicines. 
     

  • Report: Sanofi files suit over Merck’s Lantus biosimilar

  • Allergan to acquire Tobira Therapeutics

    DUBLIN and SAN FRANCISCO — Allergan has announced an acquisition aimed at making it a leader in the development of treatment for nonalcoholic steatohepatitis (NASH), a disease state seeing increased interest from drug makers. The company will be acquiring clinical-stage biotech company Tobira Therapeutics in a deal with a total potential value of $1.69 billion.
     

  • Industry responds to Biosimilar User Fee Act letter

    SILVER SPRING, Md. — The Food and Drug Administration on Friday released the Biosimilar User Fee Act (II) performance goals letter, drawing support from trade groups representing biotechnology companies. 
     

  • CPPA accredits KloudScript’s specialty-at-retail model

    OAKBROOK TERRACE, Ill. — The Center for Pharmacy Practice Accreditation (CPPA) has accredited specialty pharmacy care network KloudScript’s partnership with Illinois independent pharmacy Doc’s Pharmacy, the company announced Tuesday. This marks the first time a specialty-at-retail provider and a pharmacy have been given a joint accreditation from CPPA. 
     
X
This ad will auto-close in 10 seconds